Global Onychomycosis Market Size, Share, Trends, Industry Analysis Report: By Type, By Treatment (Topical, Oral and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) – Market Forecast, 2024 - 2032.

Global Onychomycosis Market Size, Share, Trends, Industry Analysis Report: By Type, By Treatment (Topical, Oral and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) – Market Forecast, 2024 - 2032.



The global onychomycosis market size is expected to reach USD 5,689.46 million by 2032, according to a new study by Polaris Market Research. The report “Global Onychomycosis Market Size, Share, Trends, Industry Analysis Report: By Type, By Treatment (Topical, Oral and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) – Market Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The onychomycosis market is experiencing significant growth due to increased recognition of fungal diseases and improved public awareness. This has led to early detection and better understanding of the effects of fungal infections, such as onychomycosis.

In September 2023, the Centers for Disease Control and Prevention (CDC) recognized Fungal Disease Awareness Week (FDAW). Every year, the CDC and its partners participate in initiatives and outreach efforts to raise public awareness of fungal infections. Leading up to FDAW in 2023, various events emphasized the growing challenges, complexities, and significant impacts of fungal diseases.

Furthermore, lasers have received approval from the Food and Drug Administration (FDA), and technological advancements have led to the use of lasers in the treatment of onychomycosis, contributing to the expansion of the market.

As per the Indian Dermatology Online Journal, combining topical therapy with fractional CO2 laser can enhance the effectiveness of onychomycosis treatment. Several factors, such as nail plate thickness, extent and type of onychomycosis, number of sessions, and concurrent therapy, can influence treatment results. Fractional CO2 laser treatment involves creating openings in the nail, which improves the delivery of topical drugs by three to four times over 42 days. Therefore, using fractional CO2 laser as a pre-treatment alongside topical therapy for onychomycosis can be beneficial.

Furthermore, oral treatment for onychomycosis is becoming increasingly popular among patients due to its higher success rates and shorter treatment durations compared to topical antifungals. The main treatment for this fungal infection is oral terbinafine hydrochloride. Many generic manufacturers are introducing oral treatments to address the growing prevalence of onychomycosis.

For instance, in June 2021, Glenmark Pharmaceuticals was granted approval by the U.S. FDA for their therapeutically equivalent and bioequivalent theophylline extended-release tablets, available in 450 mg and 300 mg for the treatment of onychomycosis.

Onychomycosis Market Report Highlights
  • The distal subungual onychomycosis segment dominated the market. This is due to the rising number of approvals by the FDA in response to the increasing demand for more effective medications for onychomycosis treatment.
  • The topical segment dominated the market over the forecast period as topical treatments are associated with fewer side effects.
  • The North America region dominated the market over the forecast period owing to the increased occurrence of the target disease and supportive government policies.
  • The Asia-Pacific region is expected to grow at the fastest CAGR owing to the limited access to healthcare services, poor hygiene practices, and extensive urbanization.
  • The global key market players include Bausch Health Companies Inc., Moberg Pharma AB, Abbott, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., Merck & Co., Inc., Novartis AG, Zydus Lifesciences and Sun Pharmaceutical Industries Ltd.
Polaris Market Research has segmented the onychomycosis market report based on type, treatment, and region:

Onychomycosis, Type Outlook (Revenue - USD Million, 2019 - 2032)
  • Distal Subungual Onychomycosis
  • Proximal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Others
Onychomycosis, Treatment Outlook (Revenue - USD Million, 2019 - 2032)
  • Topical
  • Oral
  • Others
Onychomycosis, Regional Outlook (Revenue - USD Million, 2019 - 2032)
  • North America
U.S.

Canada
  • Europe
Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe
  • Asia Pacific
China

India

Japan

South Korea

Indonesia

Australia

Malaysia

Vietnam

Rest of Asia Pacific
  • Latin America
Argentina

Brazil

Mexico

Rest of Latin America
  • Middle East & Africa
UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa


1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Global Onychomycosis Market Insights
4.1. Onychomycosis Market – Market Snapshot
4.2. Onychomycosis Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Rising Demand for Topical Therapies is Driving the Market Growth
4.2.1.2. Rising Advanced Technologies is Driving the Market Growth
4.2.2. Restraints and Challenges
4.2.2.1. Presence of Alternative Therapies
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Onychomycosis Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. Global Onychomycosis Market, by Type
5.1. Key Findings
5.2. Introduction
5.2.1. Global Onychomycosis Market, by Type, 2019-2032 (USD Million)
5.3. Distal Subungual Onychomycosis
5.3.1. Global Onychomycosis Market, by Distal Subungual Onychomycosis, by Region, 2019-2032 (USD Million)
5.4. Proximal Subungual Onychomycosis
5.4.1. Global Onychomycosis Market, by Proximal Subungual Onychomycosis, by Region, 2019-2032 (USD Million)
5.4.2. White Superficial Onychomycosis
5.4.2.1. Global Onychomycosis Market, by White Superficial Onychomycosis, by Region, 2019-2032 (USD Million)
5.4.3. Others
5.4.3.1. Global Onychomycosis Market, by Others, by Region, 2019-2032 (USD Million)
6. Global Onychomycosis Market, by Treatment
6.1. Key Findings
6.2. Introduction
6.2.1. Global Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
6.3. Topical
6.3.1. Global Onychomycosis Market, by Topical, by Region, 2019-2032 (USD Million)
6.4. Oral
6.4.1. Global Onychomycosis Market, by Oral, by Region, 2019-2032 (USD Million)
6.5. Others
6.5.1. Global Onychomycosis Market, by Others, by Region, 2019-2032 (USD Million)
7. Global Onychomycosis Market, by Geography
7.1. Key Findings
7.2. Introduction
7.2.1. Onychomycosis Market Assessment, By Geography, 2019-2032 (USD Million)
7.3. Onychomycosis Market – North America
7.3.1. North America: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.3.2. North America: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.3.3. Onychomycosis Market – U.S.
7.3.3.1. U.S.: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.3.3.2. U.S.: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.3.4. Onychomycosis Market – Canada
7.3.4.1. Canada: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.3.4.2. Canada: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.4. Onychomycosis Market – Europe
7.4.1. Europe: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.4.2. Europe: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.4.3. Onychomycosis Market – UK
7.4.3.1. UK: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.4.3.2. UK: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.4.4. Onychomycosis Market – France
7.4.4.1. France: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.4.4.2. France: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.4.5. Onychomycosis Market – Germany
7.4.5.1. Germany: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.4.5.2. Germany: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.4.6. Onychomycosis Market – Italy
7.4.6.1. Italy: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.4.6.2. Italy: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.4.7. Onychomycosis Market – Spain
7.4.7.1. Spain: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.4.7.2. Spain: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.4.8. Onychomycosis Market – Netherlands
7.4.8.1. Netherlands: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.4.8.2. Netherlands: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.4.9. Onychomycosis Market – Russia
7.4.9.1. Russia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.4.9.2. Russia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.4.10. Onychomycosis Market – Rest of Europe
7.4.10.1. Rest of Europe: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.4.10.2. Rest of Europe: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.5. Onychomycosis Market – Asia Pacific
7.5.1. Asia Pacific: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.5.2. Asia Pacific: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.5.3. Onychomycosis Market – China
7.5.3.1. China: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.5.3.2. China: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.5.4. Onychomycosis Market – India
7.5.4.1. India: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.5.4.2. India: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.5.5. Onychomycosis Market – Malaysia
7.5.5.1. Malaysia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.5.5.2. Malaysia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.5.6. Onychomycosis Market – Japan
7.5.6.1. Japan: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.5.6.2. Japan: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.5.7. Onychomycosis Market – Indonesia
7.5.7.1. Indonesia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.5.7.2. Indonesia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.5.8. Onychomycosis Market – South Korea
7.5.8.1. South Korea: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.5.8.2. South Korea: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.5.9. Onychomycosis Market – Australia
7.5.9.1. Australia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.5.9.2. Australia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.5.10. Onychomycosis Market – Rest of Asia Pacific
7.5.10.1. Rest of Asia Pacific: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.5.10.2. Rest of Asia Pacific: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.6. Onychomycosis Market – Middle East & Africa
7.6.1. Middle East & Africa: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.6.2. Middle East & Africa: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.6.3. Onychomycosis Market – Saudi Arabia
7.6.3.1. Saudi Arabia: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.6.3.2. Saudi Arabia: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.6.4. Onychomycosis Market – UAE
7.6.4.1. UAE: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.6.4.2. UAE: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.6.5. Onychomycosis Market – Israel
7.6.5.1. Israel: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.6.5.2. Israel: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.6.6. Onychomycosis Market – South Africa
7.6.6.1. South Africa: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.6.6.2. South Africa: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.6.7. Onychomycosis Market – Rest of Middle East & Africa
7.6.7.1. Rest of Middle East & Africa: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.6.7.2. Rest of Middle East & Africa: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.7. Onychomycosis Market – Latin America
7.7.1. Latin America: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.7.2. Latin America: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.7.3. Onychomycosis Market – Mexico
7.7.3.1. Mexico: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.7.3.2. Mexico: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.7.4. Onychomycosis Market – Brazil
7.7.4.1. Brazil: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.7.4.2. Brazil: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.7.5. Onychomycosis Market – Argentina
7.7.5.1. Argentina: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.7.5.2. Argentina: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
7.7.6. Onychomycosis Market – Rest of Latin America
7.7.6.1. Rest of Latin America: Onychomycosis Market, by Type, 2019-2032 (USD Million)
7.7.6.2. Rest of Latin America: Onychomycosis Market, by Treatment, 2019-2032 (USD Million)
8. Competitive Landscape
8.1. Expansion and Acquisition Analysis
8.1.1. Expansion
8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
9.1. Abbott
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Recent Development
9.2. Bausch Health Companies Inc.
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Product Benchmarking
9.2.4. Recent Development
9.3. Cipla Inc.
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Product Benchmarking
9.3.4. Recent Development
9.4. Merck & Co., Inc.
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Benchmarking
9.4.4. Recent Development
9.5. Moberg Pharma AB
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Product Benchmarking
9.5.4. Recent Development
9.6. Novartis AG
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Product Benchmarking
9.6.4. Recent Development
9.7. Pfizer Inc.
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Product Benchmarking
9.7.4. Recent Development
9.8. Sun Pharmaceutical Industries Ltd.
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Product Benchmarking
9.8.4. Recent Development
9.9. Teva Pharmaceutical Industries Ltd.
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Product Benchmarking
9.9.4. Recent Development
9.10. Zydus Lifesciences
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. Product Benchmarking
9.10.4. Recent Development

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings